Revolution Medicines to Present Preclinical Data at the Upcoming American Association for Cancer Research Annual Meeting 2023
Revolution Medicines, Inc. (Nasdaq: RVMD) announced it will present significant preclinical data at the AACR Annual Meeting 2023, taking place from April 14-19, 2023, in Orlando, Florida. Notable presentations include the discovery of RMC-6291, a tri-complex KRAS G12C inhibitor, and RMC-9805, a first-in-class mutant-selective KRAS G12D inhibitor that synergizes with immunotherapy in preclinical models. These innovations aim to address RAS-addicted cancers, showcasing the company's commitment to developing targeted oncological therapies. The presentations are scheduled for April 16 and 17, highlighting advancements in cancer treatment that could significantly impact future clinical strategies.
- Presentation of preclinical data at AACR Annual Meeting 2023, boosting visibility.
- RMC-6291 (KRAS G12C inhibitor) and RMC-9805 (KRAS G12D inhibitor) showing promising results.
- Potential synergistic effects of RMC-9805 with immunotherapy in preclinical studies.
- None.
REDWOOD CITY, Calif., April 06, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced the company and its collaborators will present preclinical data at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2023 being held April 14-19, 2023, in Orlando, Florida.
Details of the planned presentations are listed below:
Revolution Medicines Oral Presentations:
| Title: | Discovery of RMC-6291, a tri-complex KRASG12C(ON) inhibitor | |
| Presenter: | Jim Cregg, Ph.D. | |
| Abstract Number: | ND07 | |
| Session: | New Drugs on the Horizon: Part 2 | |
| Date/Time: | 3:45 – 4:00 p.m. Eastern on April 16, 2023 |
| Title: | RMC-9805, a first-in-class, mutant-selective, covalent and orally bioavailable KRASG12D(ON) inhibitor, promotes cancer-associated neoantigen recognition and synergizes with immunotherapy in preclinical models | |
| Presenter: | Marie Menard, Ph.D. | |
| Abstract Number: | 3475 | |
| Session: | Immune Checkpoints at Tumor Beds | |
| Date/Time: | 3:37 – 3:52 p.m. Eastern on April 17, 2023 |
Revolution Medicines Poster Presentations:
| Title: | RMC-9805, a first-in-class, mutant-selective, covalent and oral KRASG12D(ON) inhibitor that induces apoptosis and drives tumor regression in preclinical models of KRASG12D cancers | |
| Presenter: | Lingyan Jiang, Ph.D. | |
| Abstract Number: | 526/26 | |
| Session: | Novel Antitumor Agents 2 | |
| Date/Time: | 1:30 – 5:00 p.m. Eastern on April 16, 2023 |
| Title: | RMC-0708 (RM-046), a first-in-class, mutant-selective and oral KRASQ61H(ON) inhibitor that drives tumor regression in preclinical models and validates KRASQ61H as a therapeutic target | |
| Presenter: | Yu C. Yang, Ph.D. | |
| Abstract Number: | 1598/21 | |
| Session: | New Therapeutic Targeted Agents | |
| Date/Time: | 9:00 a.m. – 12:30 p.m. Eastern on April 17, 2023 |
Collaborator Oral Presentation:
| Title: | Combining KRASG12C(ON) inhibition with SHP2 and immune checkpoint blockade to enhance anti-tumor immunity and overcome development of resistance in lung cancer | |
| Abstract Number: | 5733 | |
| Session: | New Tricks for Known Targets: Novel Approaches to Inhibit Oncogenic Signaling | |
| Presentation Time: | 2:37 – 2:52 p.m. Eastern on April 18, 2023 |
Collaborator Poster Presentations:
| Title: | Bi-steric mTORC1-selective inhibitors activate 4EBP1, suppress MYC, restore anti-tumor immunity, and cooperate with immune checkpoint inhibition to elicit tumor regression | |
| Abstract Number: | LB015/7 | |
| Session: | Late-Breaking Research: Experimental and Molecular Therapeutics 1 | |
| Presentation Time: | 1:30 – 5:00 p.m. Eastern on April 16, 2023 |
| Title: | Preclinical evaluation of RM-042, an orally bioavailable inhibitor of GTP-RAS, in models of pancreatic ductal adenocarcinoma | |
| Abstract Number: | 1725/22 | |
| Session: | Oncogenes and Tumor Suppressor Genes as Targets for Therapy 2 | |
| Date/Time: | 9:00 a.m. – 12:30 p.m. Eastern on April 17, 2023 |
| Title: | Bi-steric mTORC1 inhibitors are superior to rapamycin and induce apoptotic cell death in tumor models with hyperactivated mTORC1 | |
| Abstract Number: | 4859/2 | |
| Session: | Anticancer Approaches Targeting Signal Transduction Pathways | |
| Presentation Time: | 1:30 – 5:00 p.m. Eastern on April 18, 2023 |
Additional information on the AACR Annual Meeting 2023 is available through the AACR website at: https://www.aacr.org/meeting/aacr-annual-meeting-2023/
About Revolution Medicines, Inc.
Revolution Medicines is a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) Inhibitors designed to suppress diverse oncogenic variants of RAS proteins, and RAS Companion Inhibitors for use in combination treatment strategies. The company’s RAS(ON) Inhibitors RMC-6236 (RASMULTI) and RMC-6291(KRASG12C) are currently in clinical development. Additional RAS(ON) Inhibitors in the company’s pipeline include RMC-9805 (KRASG12D) and RMC-0708 (KRASQ61H), both of which are currently in IND-enabling development, RMC-8839 (KRASG13C), and additional compounds targeting other RAS variants. RAS Companion Inhibitors in clinical development include RMC-4630 (SHP2) and RMC-5552 (mTORC1/4EBP1).
FAQ
What presentations will Revolution Medicines make at the AACR Annual Meeting 2023?
When is Revolution Medicines presenting at the AACR Annual Meeting 2023?
What is the significance of RMC-9805 in cancer treatment?
What is the focus of Revolution Medicines in the oncology sector?
How could the presentations affect RVMD stock?
